Gypenoside XLIX

Synonyms: 绞股蓝皂苷 XLIX
Gypenoside XLIX 是一种可从绞股蓝中分离得到的多功能生物活性化合物,与 SIRT1 结合的 Ka 值为 1.58 μM,作为 PPAR-α 激活剂可通过激活 Sirt1/Nrf2 信号通路抑制 TLR4 介导的 NF-κB 信号通路激活,减少 ROS 蓄积,从而减轻脓毒症肝病小鼠的肝脏炎症损伤,并可靶向 SIRT1 阻断 YAP-NLRP3 激活以改善脓毒症诱导的心肌病,抑制细胞凋亡 (Apoptosis)、细胞焦亡 (Pyroptosis)、自噬 (Autophagy)、脂质过氧化、促炎细胞因子及抗炎因子,通过抑制炎症和氧化应激减轻脓毒症诱导的脾损伤,通过靶向 PPAR-α 减轻脓毒症相关性脑病,通过抑制 IGFBP7/IGF1R 介导的程序性细胞死亡和炎症来预防急性肾损伤,并抑制细胞因子诱导的人内皮细胞中血管细胞黏附分子 - 1 的表达及活性,可用于急性肝损伤、肺损伤、心肌病、急性脾损伤、脓毒症相关性脑病、急性肾损伤、动脉粥样硬化及慢性炎症的相关研究。
产品编号: MS-O26650 纯度: 99.88% CAS No.: 94987-08-3 分子式: C52H86O21 分子量: 1047.23
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Gypenoside XLIX 是一种可从绞股蓝中分离得到的多功能生物活性化合物,与 SIRT1 结合的 Ka 值为 1.58 μM,作为 PPAR-α 激活剂可通过激活 Sirt1/Nrf2 信号通路抑制 TLR4 介导的 NF-κB 信号通路激活,减少 ROS 蓄积,从而减轻脓毒症肝病小鼠的肝脏炎症损伤,并可靶向 SIRT1 阻断 YAP-NLRP3 激活以改善脓毒症诱导的心肌病,抑制细胞凋亡 (Apoptosis)、细胞焦亡 (Pyroptosis)、自噬 (Autophagy)、脂质过氧化、促炎细胞因子及抗炎因子,通过抑制炎症和氧化应激减轻脓毒症诱导的脾损伤,通过靶向 PPAR-α 减轻脓毒症相关性脑病,通过抑制 IGFBP7/IGF1R 介导的程序性细胞死亡和炎症来预防急性肾损伤,并抑制细胞因子诱导的人内皮细胞中血管细胞黏附分子 - 1 的表达及活性,可用于急性肝损伤、肺损伤、心肌病、急性脾损伤、脓毒症相关性脑病、急性肾损伤、动脉粥样硬化及慢性炎症的相关研究。

生物实验数据

生物活性 Gypenoside XLIX is a multifunctional bioactive compound isolated from Gynostemma pentaphyllum with a Ka value of 1.58 μM for binding to SIRT1; as a PPAR-α activator, it inhibits TLR4-mediated activation of the NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with septic liver disease; it targets SIRT1 to block YAP-NLRP3 activation and ameliorate sepsis-induced cardiomyopathy; it inhibits apoptosis, pyroptosis, autophagy, lipid peroxidation, pro-inflammatory cytokines, and anti-inflammatory factors; it alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, mitigates sepsis-associated encephalopathy by targeting PPAR-α, prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation, and inhibits cytokine-induced expression and activity of vascular cell adhesion molecule-1 in human endothelial cells; it can be used for research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis, and chronic inflammation.
IC50 & Target

PPAR-α

 

体外研究
(In Vitro)

Gypenoside XLIX (0-80 μM) 在 10、20、40 和 80 μM 的浓度降低 RAW264.7 细胞的活力,在 5 μM 浓度下无显著影响。
Gypenoside XLIX (40 μM) 可通过降低 P-IκBα 和 P-P65 水平、恢复 IκBα 水平,抑制 RAW264.7 细胞中由 LPS (MS-X54539) 激活的 NF-κB 信号通路,可通过上调 PPAR-α 蛋白水平激活 LPS 刺激的 RAW264.7 细胞中的 PPAR-α。
Gypenoside XLIX (40 μM; 1 h pre-incubation) 可通过上调 Nrf2、HO-1 及 NQO1 的蛋白水平激活 LPS 刺激的 RAW264.7 细胞中的抗氧化 Nrf2 通路,从而减轻氧化应激。
Gypenoside XLIX (40 μM; 1 h pre-incubation) 可通过降低 NLRP3、ASC、Caspase1 P20、GSDMD 和 IL-1β 蛋白水平,抑制 NLRP3 炎症小体通路并减轻 LPS 刺激的 RAW264.7 细胞的焦亡。
Gypenoside XLIX (32 μM; 12 h) 可激活 Sirt1/Nrf2 信号通路,减少 ROS 的生成,并在 LPS/ATP (MS-D18391) 刺激的 MLE-12 细胞中抑制 NLRP3 炎症小体的激活。
Gypenoside XLIX (3.125-100 μM) 可高亲和力直接结合重组 SIRT1 蛋白,通过 SPR 测得的 Kd 值为 1.58 μM,在 H9C2 大鼠心肌细胞中稳定 SIRT1 蛋白,抵御热诱导的降解。
Gypenoside XLIX (40 μM; 24 h) 以 SIRT1 依赖的方式缓解 LPS 诱导的 H9C2 大鼠心肌细胞炎症与氧化应激,降低促炎细胞因子表达、氧化应激标志物水平及 NLRP3 炎症小体的激活,促进细胞中 YAP 的磷酸化、去乙酰化及蛋白酶体降解。
Gypenoside XLIX (40 μM) 可通过增强 K27 连接的泛素化作用,在过表达 YAP 的 H9C2 大鼠心肌细胞中促进 NLRP3 的转录后蛋白酶体降解,逆转 YAP 诱导的 NLRP3 上调。
Gypenoside XLIX (20-40 μM) 可降低小鼠小胶质细胞 BV-2 的存活率。
Gypenoside XLIX (10 μM; 12 h) 可降低 LPS 刺激的小鼠小胶质细胞 BV-2 中的 NO,ROS 生成,上调细胞中 PPAR-α 的表达,并抑制 p38 和 JNK MAPK 通路的激活,该效应部分依赖于 PPAR-α 的激活。
Gypenoside XLIX (10 μM; 12 h) 可降低 LPS 刺激的小鼠小胶质细胞 BV-2 中炎症蛋白 iNOS、COX-2 和 TLR4 的表达,激活细胞中的 Nrf2/Keap1 氧化应激反应通路,该效应依赖于 PPAR-α 的激活。
Gypenoside XLIX (10 μM; 12 h) 可通过调控凋亡蛋白的表达来降低 LPS 刺激的小鼠小胶质细胞 BV-2 的凋亡水平,该效应依赖于 PPAR-α 的激活。
Gypenoside XLIX (0-256 μM; 24 h) 可恢复经 Cisplatin (MS-E94993) 处理的 HK2 细胞的活力。
Gypenoside XLIX (0-128 μM; 24 h) 可降低 Cisplatin, 缺氧/复氧 (H/R) 诱导的 HK2 细胞中 KIM-1 蛋白及 KIM-1 mRNA 水平的升高,降低促炎细胞因子产生及 NF-κB 活化,抑制细胞坏死性凋亡与细胞凋亡。
Gypenoside XLIX (64 μM; overnight pre-incubation) 通过降低 IGFBP7 的表达及其与 IGF1R 的结合,在 Cisplatin 处理的 HK2 细胞中激活 IGF 通路。
Gypenoside XLIX (10-300 μM; 0.5-24 h) 可通过 PPAR-α 依赖通路抑制 TNF-α 诱导的人脐静脉内皮细胞 (HUVECs) 中 VCAM-1 启动子活性 (IC50 = 186.8 μM)、mRNA 表达、总蛋白表达、表面 VCAM-1 表达。

Western Blot Analysis

Cell Line: LPS-stimulated RAW264.7
Concentration: 40 μM
Incubation Time: 1 h (pre-incubation)
Result: Significantly reduced LPS-induced increases in P-IκBα, P-P65 protein levels.
Reversed LPS-induced decreases in IκBα protein levels.\n
Significantly increased Nrf2,, PPAR-α, HO-1 and NQO1 protein levels.
Significantly reduced LPS-induced increases in NLRP3, ASC, Caspase1 P20, GSDMD, and IL-1β protein levels.

Western Blot Analysis

Cell Line: LPS-stimulated mouse microglial BV-2 cells
Concentration: 10 μM (pretreated before LPS stimulation)
Incubation Time: 12 h (pretreated before LPS stimulation)
Result: Increased PPAR-α protein expression relative to LPS-only treated cells.
Reduced p-p38 and p-JNK protein expression relative to LPS-only treated cells.
These effects were partially reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nReduced iNOS, COX-2, and TLR4 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nIncreased Nrf2 protein expression relative to LPS-only treated cells.
Reduced Keap1 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).\nReduced Bax protein expression relative to LPS-only treated cells.
Increased Bcl-2 protein expression relative to LPS-only treated cells; these effects were reversed by co-treatment with 5 μM PPAR-α inhibitor GW6471 (pretreated for 30 min before Gypenoside XLIX).

Cell Viability Assay

Cell Line: HK2 (human renal tubular epithelial cells)
Concentration: 32 μM (pre-incubated before 24 h Cisplatin treatment); 64 μM (pre-incubated before 24 h Cisplatin treatment); 128 μM (pre-incubated before 24 h Cisplatin treatment)
Incubation Time: 12 h (pre-incubation); 24 h (cisplatin treatment)
Result: Markedly restored HK2 cell viability in response to Cisplatin treatment.

Western Blot Analysis

Cell Line: HK2 (hypoxia/reoxygenation (H/R)-treated human renal tubular epithelial cells)
Concentration: 64 μM (pre-incubated before H/R treatment)
Incubation Time: 12 h (hypoxia); 6 h (reoxygenation)
Result: Downregulated H/R-induced increases in protein levels of RIPK1, RIPK3, and cleaved caspase-3.

RT-PCR

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 10-300 μM
Incubation Time: 30 min pre-incubation before 5 h TNF-α stimulation
Result: Concentration-dependently decreased TNF-α-induced VCAM-1 mRNA overexpression (a ~3-fold increase in controls).

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 10-300 μM
Incubation Time: 30 min pre-incubation before 5 h TNF-α stimulation
Result: Concentration-dependently decreased TNF-α-induced VCAM-1 protein overexpression (a ~3-fold increase in controls).

ELISA Assay

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 10-300 μM
Incubation Time: 24 h pre-incubation before 8 h TNF-α stimulation
Result: Concentration-dependently decreased TNF-α-induced cell surface VCAM-1 expression, reducing control activity to 51.4 ± 3.7% at 300 μM.
体内研究
(In Vivo)

Gypenoside XLIX (40 mg/kg; i.p.; single dose/daily; 4 days) 可通过激活 Sirt1/Nrf2 信号通路来抑制 NF-κB/PPAR-α/NLRP3 通路,改善肝功能异常、减轻炎症反应、氧化应激、脂质蓄积及细胞焦亡、线粒体通路凋亡及过度线粒体自噬,从而显著缓解小鼠中由盲肠结扎和穿刺 (CLP) 诱导的急性肝损伤。
Gypenoside XLIX (10-40 mg/kg; i.p.; daily; 5 days) 呈剂量依赖性缓解脓毒症诱导的心肌病,其中 40 mg/kg 剂量的治疗效果最为显著,包括 80% 的存活率、炎症与氧化应激水平降低、心功能恢复,以及通过激活 SIRT1 抑制 YAP-NLRP3 通路。
Gypenoside XLIX (20 mg/kg; i.p.; daily; 4 days) 可通过降低 ROS 和 MDA 水平、增强抗氧化酶活性及调控促炎与抗炎介质的表达,显著减轻脓毒症雄性 BALB/c 小鼠中由 CLP 诱导的急性脾脏炎症和氧化应激。
Gypenoside XLIX (40 mg/kg; i.p.; daily; 5 days) 可通过激活 PPAR-α 缓解 CLP 诱导的 C57BL/6 小鼠中脓毒症相关性脑病,将生存率提升至 73.33%,同时减轻神经炎症、氧化应激、细胞凋亡及血脑屏障损伤,并恢复认知功能。
Gypenoside XLIX (25-100 mg/kg; i.p.; daily; 3 days) 可通过抑制肾脏炎症、坏死性凋亡、细胞凋亡以及 IGFBP7/IGF1R 通路失调,显著保护雄性 C57BL/6 小鼠免受 Cisplatin 、肾缺血再灌注诱导的急性肾损伤 (AKI),同时可显著降低血清肌酐、尿素氮 (BUN)、肾小管损伤评分,以及促炎症和细胞死亡标志物水平。

Animal Model: BALB/c (male, 6 weeks old, 20-25 g CLP-induced sepsis model)
Dosage: 40 mg/kg
Administration: i.p.; single dose/daily; 4 consecutive days
Result: Ameliorated the CLP-induced darkening of liver tissue and maintained the structural integrity of the liver; reduced the severity of hepatocyte vacuolar degeneration, necrosis, and architectural disarray, resulting in a liver structure that appeared more normal and orderly arranged.
Significantly reduced the serum levels of the liver dysfunction biomarkers ALT and AST.
Decreased the mRNA expression levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, as well as the inflammatory mediator iNOS, while increasing the mRNA expression level of the anti-inflammatory cytokine IL-10.
Significantly reduced the protein expression levels of TLR4 and iNOS.
Increased the protein levels of IκBα in liver tissue and decreased the protein levels of p-p65, thereby inhibiting the activation of the NF-κB signaling pathway.
Reduced the levels of MDA and the protein levels of CYP2E1 in liver tissue, while increasing the levels of T-AOC, CAT, and GSH, as well as the protein levels of Nrf2 and HO-1, also reduced the accumulation of ROS in the liver, thereby effectively alleviating oxidative stress-induced injury.
Increased the protein levels of PPAR-α in liver tissue and reduced the number of lipid droplets (as detected by Oil Red O staining), thereby alleviating hepatic lipid accumulation.
Reduced the protein expression levels of NLRP3, ASC, Caspase-1 p20, GSDMD, and IL-1β in liver tissue, thereby inhibiting the occurrence of hepatocyte pyroptosis.
Iincreased the protein expression levels of Sirt1 and Nrf2 in lung tissue, thereby activating the Sirt1/Nrf2 signaling pathway.
Significantly reduced the number of TUNEL-positive apoptotic cells in lung tissue; it decreased the protein expression of cleaved Caspase-3, Cytochrome c, and Bax, while increasing the protein expression of the anti-apoptotic marker Bcl-2.
Reduced the protein expression levels of the mitochondrial autophagy-related markers Pink1, Parkin, and the LC3B II/I ratio, while increasing the protein expression of p62, thereby inhibiting excessive mitochondrial autophagy.
Animal Model: C57BL/6 (male, 8 weeks old, cecal ligation and puncture surgery-induced sepsis)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.p.; daily; 5 days
Result: Increased survival rate, with significant improvement at 20 and 40 mg/kg.
Significantly reduced sepsis model scores at 20 and 40 mg/kg.
Significantly reduced cardiac wet-to-dry weight ratios at 20 and 40 mg/kg.
Reduced serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels at all three doses, with the most significant reduction at 40 mg/kg.
Significantly mitigated CLP-induced body weight loss at 20 and 40 mg/kg.
Significantly reduced cardiomyocyte disorganization, interstitial gap enlargement, and lymphocyte infiltration, with improved H&E staining and reduced histopathological scores at 40 mg/kg.
Reduced left ventricular internal dimension in diastole/systole (LVIDd/LVIDs) ratio, increased left ventricular anterior wall thickness in diastole (LVAWd), left ventricular posterior wall thickness in diastole (LVPWd), fractional shortening (FS), and ejection fraction (EF) at 40 mg/kg compared to untreated mice, reversing ventricular dilation and systolic dysfunction.
Reduced cardiac mRNA expression of pro-inflammatory cytokines IL-1β, IL-6, iNOS, and TNF-α, increased anti-inflammatory cytokine IL-10 mRNA expression, and reduced protein levels of iNOS, COX-2, and TLR4 at 40 mg/kg.
Increased cardiac glutathione (GSH), catalase (CAT), and total antioxidant capacity (T-AOC) levels, reduced malondialdehyde (MDA) levels, reversed CLP-induced increases in Keap1 protein and decreases in Nrf2 protein, and reduced reactive oxygen species (ROS) levels at 40 mg/kg compared to untreated mice.
Increased cardiac SIRT1 mRNA and protein expression, reduced total YAP protein levels, increased phosphorylated YAP levels, reduced acetylated YAP levels, and reduced NLRP3 protein expression at 40 mg/kg compared to untreated mice; promoted K27-linked polyubiquitination of NLRP3 to drive its degradation.
Animal Model: BALB/c (male, 6 weeks old, 20-25 g, CLP-induced sepsis)
Dosage: 20 mg/kg
Administration: i.p.; daily; 4 days
Result: Mitigated CLP-induced splenic histopathological damage, restoring clear demarcation between red and white marrow with well-defined structures.
Reduced CLP-induced splenic malondialdehyde (MDA) levels and increased catalase (CAT), glutathione (GSH), and total antioxidant capacity (T-AOC) levels in spleen tissue.
Inhibited CLP-induced splenic reactive oxygen species (ROS) accumulation.
Downregulated mRNA and protein levels of pro-inflammatory mediators iNOS, COX-2, TNF-α, IL-6, and IL-1β in spleen tissue.
Upregulated mRNA levels of the anti-inflammatory cytokine IL-10 in spleen tissue.
Animal Model: C57BL/6 (6-8 weeks old; sepsis-associated encephalopathy induced by caecal ligation and puncture)
Dosage: 40 mg/kg
Administration: i.p.; daily; 5 days
Result: Achieved a 73.33% survival rate in CLP-induced SAE mice.
Reduced neurological deficit scores.
Decreased brain water content.
Mitigated cerebral cortex structural damage and reduced microglial hyperplasia.
Increased time spent and distance travelled in the central area of the open field test; increased exploration of open arms in the elevated plus maze test; reduced escape latency in the Morris water maze test.
Decreased Evans blue leakage, downregulated MMP9 protein expression, and upregulated claudin protein expression.
Decreased mRNA expression of proinflammatory cytokines IL-1β, TNF-α, IL-6, and iNOS; increased mRNA expression of anti-inflammatory cytokine IL-10; downregulated protein expression of iNOS, COX-2, TLR4, and p-p65.
Increased CAT activity, GSH content, and T-AOC activity; decreased MDA content and cerebral cortex ROS levels; upregulated Nrf2 protein expression and downregulated Keap1 protein expression.
Reduced TUNEL-positive cells in the cerebral cortex; downregulated Bax and Cyto-C protein expression; upregulated Bcl-2 protein expression.
Increased PPAR-α protein expression in brain tissue and downregulated activation of downstream MAPK signalling proteins (p-p38 and p-JNK).
Reduced IBA1 protein expression in brain tissue.
Animal Model: C57BL/6 (male, 6-8 weeks old, Cisplatin/renal ischemia-reperfusion-induced AKI)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 3 consecutive days (first dose 6 hours pre-cisplatin)
Result: Significantly suppressed the cisplatin-induced increase in serum creatinine and blood urea nitrogen levels.
Significantly reduced tubular necrosis, dilation, and cast formation, with tubular injury scores decreased to levels significantly lower than the cisplatin group.
Significantly reduced cisplatin-induced upregulation of KIM-1 mRNA and protein levels in kidney tissue.
Significantly reduced the percentage of TNF-α-positive cells in kidney tissue, and suppressed cisplatin-induced upregulation of Tnf-α, Il-6, and Mcp-1 mRNA levels in kidney tissue.
Significantly reduced cisplatin-induced increases in p-P65, RIPK1, RIPK3, and cleaved caspase-3 protein levels in kidney tissue.
Reduced IGFBP7 mRNA and protein levels, and increased p-IGF1R protein levels in kidney tissue, while decreasing the binding of IGFBP7 to IGF1R.
性状 固体
颜色 White to light yellow

化学信息

分子量 1047.23
分子式 C52H86O21
CAS No. 94987-08-3
别名 绞股蓝皂苷 XLIX

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (9.55 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (4.77 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (119.36 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9549 mL4.7745 mL9.5490 mL23.8725 mL
5 mM0.1910 mL0.9549 mL1.9098 mL4.7745 mL
10 mM0.0955 mL0.4775 mL0.9549 mL2.3873 mL
15 mM0.0637 mL0.3183 mL0.6366 mL1.5915 mL
20 mM0.0477 mL0.2387 mL0.4775 mL1.1936 mL
25 mM0.0382 mL0.1910 mL0.3820 mL0.9549 mL
30 mM0.0318 mL0.1592 mL0.3183 mL0.7958 mL
40 mM0.0239 mL0.1194 mL0.2387 mL0.5968 mL
50 mM0.0191 mL0.0955 mL0.1910 mL0.4775 mL
60 mM0.0159 mL0.0796 mL0.1592 mL0.3979 mL
80 mM0.0119 mL0.0597 mL0.1194 mL0.2984 mL
100 mM0.0095 mL0.0477 mL0.0955 mL0.2387 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

绞股蓝皂苷 XLIX 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础